<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, the most advanced vaccine approach to exploit the new knowledge on PC function is a live attenuated AD169 whole virion vaccine (V160), in which PC expression was restored by repairing a frameshift mutation in the UL131 gene [
 <xref rid="B81-vaccines-07-00070" ref-type="bibr">81</xref>]. A phase II clinical trial of V160 in healthy seronegative women is ongoing (
 <uri xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov</uri> NCT03486834), while an mRNA based vaccine containing the PC and gB (mRNA-1647) is in a phase I trial (
 <uri xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov</uri> NCT03382405).
</p>
